Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 74.87 USD 0.65% Market Closed
Market Cap: 11.9B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Bio-Techne Corp
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bio-Techne Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Bio-Techne Corp
NASDAQ:TECH
Operating Income
$248.5m
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
5%
Thermo Fisher Scientific Inc
NYSE:TMO
Operating Income
$7.4B
CAGR 3-Years
-12%
CAGR 5-Years
12%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
Operating Income
$4.5B
CAGR 3-Years
-14%
CAGR 5-Years
9%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
Operating Income
$1.1B
CAGR 3-Years
3%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Operating Income
$1.6B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
37%
IQVIA Holdings Inc
NYSE:IQV
Operating Income
$2.2B
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
14%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.8B USD
Industry
Life Sciences Tools & Services

Bio-Techne Corp. stands at the forefront of scientific progress, intertwining innovation with essential biotechnology solutions. Founded in 1976 and headquartered in Minneapolis, the company has evolved from its roots in producing protein research reagents to a diversified powerhouse, supporting the life sciences and clinical diagnostics sectors. Bio-Techne's expansive portfolio encompasses cutting-edge tools and technologies allowing researchers to delve deeper into cellular analysis, gene expression, and molecular diagnostics. With brands like R&D Systems, Novus Biologicals, and ProteinSimple under its belt, the company empowers scientists worldwide to unlock new discoveries, simulate complex biological processes, and ultimately contribute to advancements in healthcare and life sciences. For investors, Bio-Techne presents a compelling opportunity as it operates in a rapidly growing market fueled by increasing demand for precision medicine and advanced research capabilities. The company has demonstrated robust financial performance, marked by consistent revenue growth and healthy profit margins, driven by its commitment to research and development. As Bio-Techne continues to expand its product offerings and enhance its technological capabilities through strategic acquisitions, it stands poised to capture greater market share and drive shareholder value. With a seasoned management team guided by a focus on innovation and customer-centric solutions, Bio-Techne is not just responding to market trends but actively shaping the future of biotechnology.

TECH Intrinsic Value
55.32 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Bio-Techne Corp's Operating Income?
Operating Income
248.5m USD

Based on the financial report for Jun 30, 2024, Bio-Techne Corp's Operating Income amounts to 248.5m USD.

What is Bio-Techne Corp's Operating Income growth rate?
Operating Income CAGR 10Y
5%

Over the last year, the Operating Income growth was -15%.

Back to Top